Bacterial cell wall and membrane permeability synergy

Bacterial cell wall and membrane permeability synergy is a therapeutic strategy rather than a single molecular target, focusing on the concurrent disruption of the bacterial cell wall and cytoplasmic membrane to enhance antimicrobial efficacy (PubMed: 31405115). This approach is primarily utilized to combat multi-drug resistant (MDR) Gram-negative bacteria, where the outer membrane serves as a formidable barrier to many antibiotics. By employing cell wall synthesis inhibitors like beta-lactams or glycopeptides, the structural integrity of the peptidoglycan layer is compromised, which can facilitate the action of membrane-active agents such as polymyxins or daptomycin (Frontiers in Microbiology, 2020). This interaction often results in a "self-promoted uptake" mechanism or increased susceptibility to osmotic lysis. Clinically, this synergy is evaluated using the Fractional Inhibitory Concentration Index (FICI) to determine if the combination is significantly more effective than the sum of its parts (Journal of Antimicrobial Chemotherapy, 2017). While promising for treating recalcitrant infections, these combinations require careful monitoring for cumulative toxicities, particularly nephrotoxicity and neurotoxicity associated with membrane-disrupting agents (Nature Microbiology, 2019). Ultimately, this strategy represents a shift from single-target drug development to systems-level envelope disruption to overcome established resistance mechanisms.

Other names

Cell wall-membrane synergyAntibiotic synergyEnvelope-directed synergyDual-envelope targetingCombination antibiotic therapySynergistic bacterial envelope disruption

Synergistic disruption of the bacterial envelope where cell wall inhibitors (e.g., beta-lactams) facilitate membrane damage or increased drug uptake by membrane-active agents (e.g., polymyxins) (PubMed: 31405115).